Navigation Links
TechniScan Secures $10 Million Equity Financing Facility
Date:1/18/2011

SALT LAKE CITY, Jan. 18, 2011 /PRNewswire/ -- TechniScan (OTC Bulletin Board: TSNI), a medical device company engaged in the development and commercialization of an automated 3D breast ultrasound imaging system, announced today that it has signed a $10 million equity purchase agreement with Southridge Partners II, LP.

"We are pleased to have secured this equity financing facility with Southridge, a forward thinking institutional investor, which provides future flexibility in capital raising," said Dave Robinson, chief executive officer of TechniScan. "We plan to use the proceeds, as needed, to support our clinical studies of Warm Bath Ultrasound breast imaging technology."

Pursuant to the purchase agreement, TechniScan has the right to sell to Southridge up to $10 million of its common stock over a twenty-four month period. TechniScan will have the right, but is not obligated, to sell stock to Southridge depending on certain conditions as set forth in the purchase agreement.

"Southridge is committed to working with TechniScan in its vital research in developing better breast cancer diagnostics and is pleased to be the company's equity investor," said Stephen Hicks, chief executive officer of Southridge.

A more complete and detailed description of the purchase agreement is set forth in TechniScan's current report on Form 8-K filed today with the Securities and Exchange Commission.

The offer and sale of the shares of TechniScan's common stock issuable under the facility have not been registered under the Securities Act of 1933, as amended.  Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.  TechniScan has agreed to file within 30 days a registration statement on Form S-1, covering the resale of the common stock issued and issuable in accordance with the terms of the facility.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About TechniScan

TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. TechniScan's Warm Bath Ultrasound™ (WBU™) imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.tsni.com.

Forward Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate, "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "company") to be materially different from those expressed or implied by such forward-looking statements. The company's future operating results are dependent upon many factors, including risk factors discussed in the company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the company's Annual Report on Form 10-K filed on March 22, 2010. The company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Dave Robinson

TechniScan, Inc

(801) 994-2965

drobinson@tsni.com




'/>"/>
SOURCE TechniScan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
3. TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
4. Patent Awarded to the Design of TechniScans Unique 3-D Breast Imaging System
5. TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
6. TechniScan, Inc. Announces Restructuring of Convertible Debt
7. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. GeoVax Secures $10 Million Financing Commitment
10. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
11. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The Texas ... in recently to the labor and delivery team at Women’s Hospital at Renaissance in ... who give birth at the hospital and decide to donate. , “Women’s Hospital ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... , ... Intellitec Solutions announced the publication of a case ... GP solution that integrates to their PointClickCare EHR software package. With the guidance ... Grove now has the capability to achieve its goal for a comprehensive EHR ...
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s ... is the premier online modeling resource for fluorescence microscopists and optical system designers, ... during last 5 years spanning the globe, SearchLight has become a tremendously popular ...
Breaking Medicine News(10 mins):